Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection

Medicine (United States)

Volumn 95, Issue 10, 2016, Pages

  Yang, Wan Ting ^d,g   Wu, Li Wei ^h   Tseng, Tai Chung ^a,i   Chen, Chi Ling ^c   Yang, Hung Chih ^b,f   Su, Tung Hung ^b,c   Wang, Chia Chi ^a,i   Kuo, Stephanie Fang Tzu ^k   Liu, Chen Hua ^b,c,d   Chen, Pei Jer ^b   Chen, Ding Shinn ^b,j   Liu, Chun Jen ^b,c,l   Kao, Jia Horng ^b,c,d,e  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b Division of Gastroenterology   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d Hepatitis Research Center   (Taiwan)

^e Department of Medical Research ^*  (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

ⁱ TZU CHI UNIVERSITY   (Taiwan)

^j GENOMICS RESEARCH CENTER   (Taiwan)

^k ST VINCENT S HOSPITAL   (Australia)

^l Taiwan Liver Disease Consortium (TLC)   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; VIRUS RNA; HEPATITIS C ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; AGED; CARCINOMA, HEPATOCELLULAR; COMPLICATION; FORECASTING; GENETICS; GENOTYPE; HEPACIVIRUS; IMMUNOLOGY; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COINFECTION; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; YOUNG ADULT;

EID: 84962624443     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002995     Document Type: Article

References (39)

1. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int. 2009;3:517-525.
2. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024-1029.
3. Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011;29:3643-3650.
4. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582-592.
5. Fattovich G, Tagger A, Brollo L, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis. 1991;163: 400-402.
6. Sato S, Fujiyama S, Tanaka M, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol. 1994;21:159-166.
7. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084-2086.
8. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141:517-525.
9. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-1149.
10. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
11. Lin DY, Sheen IS, Chiu CT, et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: A longitudinal study. J Clin Ultrasound. 1993;21:303-308.
12. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
13. Hung CH, Lu SN, Wang JH, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol. 2003;38:153-157.
14. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
15. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004;41:659-666.
16. Tseng TC, Liu CJ, Chen CL, et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis. 2013;208: 584-593.
17. Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis. 2012;206:1521-1531.
18. Tseng TC, Liu CJ, Chen CL, et al. Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. Aliment Pharmacol Ther. 2015;41:949-960.
19. Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012;55:68-76.
20. Hsu CS, Liu CJ, Lai MY, et al. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology. 2007;50:310-315.
21. Lee MH, Yang HI, Lu SN, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol. 2010;28:4587-4593.
22. Park Y, Lee JH, Kim BS, et al. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol. 2010;48: 2253-2256.
23. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885-894.
24. Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339-345.
25. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954-1961.
26. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis. Hepatology. 2015;61:292-302.
27. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
28. Lin CL, Liu CH, Wang CC, et al. Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B. J Clin Gastroenterol. 2015;49:705-713.
29. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137:693-695.
30. Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003;278:591-607.
31. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference. Hepatology. 2009;50:46-55.
32. Hiraga N, Imamura M, Hatakeyama T, et al. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol. 2009;51:1046-1054.
33. Chu CM, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci. 2013;58:275-281.
34. Huang LR, Wohlleber D, Reisinger F, et al. Intrahepatic myeloidcell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nature Immunol. 2013;14:574-583.
35. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Med. 1998;4:1065-1067.
36. Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118:683-694.
37. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084-1089.
38. Liu J, Tseng TC, Yang HI, et al. Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: external validation of a scoring system. J Infect Dis. 2015;211:1566-1573.
39. Liu CJ, Chu YT, Shau WY, et al. Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut. 2014;63:506-514.